Brief: Hansoh Pharmaceutical Says EMA Starts Reviewing Marketing Authorization Application For Aumolertinib
11/10/2026 11:45
BRIEF-Hansoh Pharmaceutical Says EMA Starts Reviewing Marketing Authorization Application For Aumolertinib Oct 11 (Reuters) - Hansoh Pharmaceutical Group Company Limited 3692.HK:
SAYS IT RESUBMITTED EU MARKETING AUTHORIZATION APPLICATION FOR AUMOLERTINIB TO EMA
SAYS EMA VALIDATED APPLICATION AND REVIEW PROCEDURE HAS BEGUN
Further company coverage: 3692.HK
(Reporting by Beijing Newsroom)
((yukun.zhang@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion